{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:15:09Z","timestamp":1788556509292,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109316","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:07:22Z","timestamp":1770826042000},"page":"109316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1\u2013high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotsawaj","family":"Runglodvatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-8372","authenticated-orcid":false,"given":"Jacky\u00a0Yu-Chung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-2770","authenticated-orcid":false,"given":"Chin Heng","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-9174","authenticated-orcid":false,"given":"Gwo Fuang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Hin","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitlada","family":"Juengsamarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-5321","authenticated-orcid":false,"given":"Julie R","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyssa","family":"Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candy","family":"Bermingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109316_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2026.109316_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107177","article-title":"Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States","volume":"179","author":"Divan","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109316_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102545","article-title":"Immunotherapy-based combinations in metastatic NSCLC","volume":"116","author":"Desai","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109316_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217241","article-title":"Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: current evidence and future directions","volume":"604","author":"Gang","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109316_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."},{"key":"10.1016\/j.lungcan.2026.109316_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154470","article-title":"Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances","volume":"246","author":"Dehghani","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109316_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109316_b0040","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109316_b0045","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109316_b0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"issue":"Suppl 36","key":"10.1016\/j.lungcan.2026.109316_b0055","article-title":"ARC-7: randomized phase 2 study of domvanalimab + zimberelimab \u00b1 etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)","volume":"40","author":"Johnson","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109316_b0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cllc.2023.12.010","article-title":"STAR-121: a phase III randomized study of domvanalimab and zimberelimab in combination with chemotherapy versus pembrolizumab with chemotherapy in untreated metastatic non-small cell lung cancer with no actionable gene alterations","volume":"25","author":"Rodriguez-Abreu","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109316_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0345-9","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109316_b0070","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-23-2455","article-title":"Fc-silent anti-TIGIT antibodies potentiate antitumor immunity without depleting regulatory T cells","volume":"84","author":"Piovesan","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109316_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.736955","article-title":"Preclinical characterization of GLS-010 (zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer","volume":"11","author":"Lou","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109316_b0080","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/ijgc-2023-004705","article-title":"Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study","volume":"33","author":"Xia","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.lungcan.2026.109316_b0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","article-title":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study","volume":"164","author":"Lin","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"10183","key":"10.1016\/j.lungcan.2026.109316_b0090","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109316_b0095","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10274","key":"10.1016\/j.lungcan.2026.109316_b0100","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109316_b0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109316_b0110","unstructured":"Merck & Co., Inc. Merck provides update on KeyVibe and KEYFORM clinical development programs evaluating investigational vibostolimab and favezelimab fixed-dose combinations with pembrolizumab. Accessed 25 March 2025. https:\/\/www.merck.com\/news\/merck-provides-update-on-keyvibe-and-keyform-clinicaldevelopment-programs-evaluating-investigational-vibostolimab-and-favezelimabfixed-dose-combinations-with-pembrolizumab. 2024."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109316_b0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109316_b0120","unstructured":"BeiGene, Ltd. BeiGene provides update on the cciperlimab (BGB-A1217) clinical development program. Accessed 6 April 2025. https:\/\/ir.beigene.com\/news\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/4f7a71c1-cb84-4fa6-b562-65c239f04bc6. 2025."},{"key":"10.1016\/j.lungcan.2026.109316_b0125","unstructured":"Genentech, Inc. Genentech provides update on phase II\/III Skyscraper-06 study in metastatic non-squamous non-cmall cell lung cancer. Accessed 6 April 2025. https:\/\/www.gene.com\/media\/press-releases\/15029\/2024-07-03\/genentech-provides-update-on-phase-iiiii. 2024."},{"key":"10.1016\/j.lungcan.2026.109316_b0130","unstructured":"F. Hoffmann-La Roche Ltd. Roche reports update on phase III SKYSCRAPER-01 study results. Accessed 24 April 2025. https:\/\/www.roche.com\/media\/releases\/med-cor-2024-11-26. 2024."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109316_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-cell effector function, depletion of Tregs, and direct killing of tumor cells: the multiple mechanisms of action of a-TIGIT antagonist antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109316_b0140","doi-asserted-by":"crossref","unstructured":"K.E. Sivick Gauthier, D. Piovesan, A.E.d. Groot, A.E. Anderson, R.D. Ray, N.K. Serwas, S. Cho, A. Patnaik, P. Foster, C.G. Mitchell, H. Singh, X. Zhao, L. Seitz, N. Walker, M.J. Walters, 475Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells, J. Immunother. Cancer 11(Suppl 1) (2023) A534\u2013A534, https:\/\/jitc.bmj.com\/content\/11\/Suppl_1\/A534.","DOI":"10.1136\/jitc-2023-SITC2023.0475"},{"key":"10.1016\/j.lungcan.2026.109316_b0145","article-title":"The complex role of regulatory T Cells in immunity and aging","volume":"11","author":"Rocamora-Reverte","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109316_b0150","doi-asserted-by":"crossref","unstructured":"S. Peters, R. Herbst, H. Horinouchi, et al. SKYSCRAPER-01: a phase III, randomized trial of tiragolumab + atezolizumab versus placebo + atezolizumab in patients with previously untreated PD-L1-high, locally advanced unresectable or metastatic NSCLC. Presented at the American Association for Cancer Research Annual Meeting, April 25\u201330, 2025 (unpublished results), Chicago, Illinois.","DOI":"10.1158\/1538-7445.AM2025-CT051"},{"key":"10.1016\/j.lungcan.2026.109316_b0155","doi-asserted-by":"crossref","first-page":"S997","DOI":"10.1016\/j.annonc.2025.08.2477","article-title":"1853MO Efficacy and safety of rilvegostomig, an anti-PD-1\/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-na\u00efve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01","volume":"36","author":"Cho","year":"2025","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109316_b0160","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","article-title":"Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms","volume":"74","author":"Sundstrom","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2026.109316_b0165","doi-asserted-by":"crossref","unstructured":"C. Mathias, Y. Goto, C. Gross-Ophoff-Mueller, S. Lu, D. Rodriguez-Abreu, A. Zer, M.W. Drachsler, M. Gong, J. Hurlock, J. Tyszecki, B.C. Cho, ARTEMIDE-Lung03: a phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1, J. Clin. Oncol. 43 (Suppl 16) (2025) TPS8653, https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.TPS8653.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8653"},{"issue":"Suppl 16","key":"10.1016\/j.lungcan.2026.109316_b0170","volume":"41","author":"Rodriguez-Abreu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109316_b0175","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109316_b0180","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3892\/mco.2017.1209","article-title":"ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site","volume":"6","author":"Grajales-\u00c1lvarez","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109316_b0185","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109316_b0190","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.21037\/jtd.2019.08.29","article-title":"Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?","volume":"12","author":"Lee","year":"2020","journal-title":"J. Thorac. Dis."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:58:26Z","timestamp":1776124706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S0169500226000607"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109316","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1\u2013high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109316"}}